Universal health coverage depends on affordable medicines. But pushing down prices without also investing in quality assurance will increase the sale of substandard and falsified drugs, warns Elizabeth Pisani.
The global prevalence of diabetes mellitus is increasing alarmingly. However, the quality of vital medicines and medical products used to treat and monitor diabetes remains uncertain but of potential great public health significance. Here, we review the available evidence on the quality of antidiabetic medicines and supplies for self-monitoring of blood glucose (SMBG) and discuss their potential impact for the patients and society.
To tackle one of the most urgent public health crises facing the world today – antimicrobial resistance (AMR) – universal health coverage (UHC) must be realized. It’s time to take action by ensuring that everyone has access to safe, effective, quality-assured medicines.
When a poor country becomes wealthier, it's a good thing, right? Not if the country is trying to buy essential medicines.
This month marks the one-year anniversary of our Medicines We Can Trust campaign. To commemorate our first campaign milestone, below you’ll see a snapshot of progress over the last year, including a social media toolkit that we hope you’ll share on your channels.
Evolution of Rifampin resistance in Escherichia coli and Mycobacterium smegmatis due to substandard drugs
Poor-quality medicines undermine the treatment of infectious diseases, such as tuberculosis, which require months of treatment with rifampin and other drugs.
Every person has the right to expect that when they use a medical product, whether medicine, vaccine or diagnostic kit, it works. But too often, that is not the case. Substandard medical products result from errors, negligence or poor practice in manufacturing, transportation and/or storage.